MediWound grants BexPharm exclusive marketing rights to NexoBrid in South Korea
Around 10,000 patients with severe burns are hospitalized every year in South Korea and primarily are treated at about 10 burn centers. The easy-to-use, topically-applied pharmaceutical product ‘NexoBrid’
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.